BACKGROUND: The long-term consequences of wasting among HIV-infected persons are not known. DESIGN: HIV-infected men surviving ≥2 years based on Kaplan-Meier analysis after a clinical diagnosis or weight trajectory consistent with wasting and with available physical function assessment data [grip strength, gait speed, and quality of life (QoL)] were matched to HIV-infected and uninfected men without wasting. METHODS: Matching criteria at the functional assessment included age, calendar year, and CD4 T-cell count and plasma HIV-1 RNA (HIV-infected only). Multivariable linear regression analyses adjusted for age, cohort, race, hepatitis C status, and number of comorbid illnesses were used to assess the impact of wasting on subsequent physical function. RESULTS: Among 85 HIV-infected men surviving ≥2 years after wasting, we evaluated physical function outcomes compared with 249 HIV-infected and 338 HIV-uninfected men with no historical wasting. In multivariable regression models, HIV-infected men with prior wasting had lower grip strength and poorer physical QoL than HIV-infected men with no wasting (P ≤ 0.03), and poorer physical QoL, but higher mental QoL than HIV-uninfected men (P ≤ 0.05). When controlling for measures of immune suppression (nadir CD4 T-cell count/AIDS, the association between wasting and physical QoL was markedly attenuated, whereas there was minimal impact on the association between wasting and grip strength. CONCLUSIONS: HIV-infected wasting survivors had weaker grip strength compared with HIV-infected persons without wasting; immune suppression was associated only with physical QoL. HIV-infected survivors of wasting may represent a population of adults at increased risk for physical function decline.
BACKGROUND: The long-term consequences of wasting among HIV-infectedpersons are not known. DESIGN:HIV-infectedmen surviving ≥2 years based on Kaplan-Meier analysis after a clinical diagnosis or weight trajectory consistent with wasting and with available physical function assessment data [grip strength, gait speed, and quality of life (QoL)] were matched to HIV-infected and uninfected men without wasting. METHODS: Matching criteria at the functional assessment included age, calendar year, and CD4 T-cell count and plasma HIV-1 RNA (HIV-infected only). Multivariable linear regression analyses adjusted for age, cohort, race, hepatitis C status, and number of comorbid illnesses were used to assess the impact of wasting on subsequent physical function. RESULTS: Among 85 HIV-infectedmen surviving ≥2 years after wasting, we evaluated physical function outcomes compared with 249 HIV-infected and 338 HIV-uninfectedmen with no historical wasting. In multivariable regression models, HIV-infectedmen with prior wasting had lower grip strength and poorer physical QoL than HIV-infectedmen with no wasting (P ≤ 0.03), and poorer physical QoL, but higher mental QoL than HIV-uninfectedmen (P ≤ 0.05). When controlling for measures of immune suppression (nadir CD4 T-cell count/AIDS, the association between wasting and physical QoL was markedly attenuated, whereas there was minimal impact on the association between wasting and grip strength. CONCLUSIONS:HIV-infected wasting survivors had weaker grip strength compared with HIV-infectedpersons without wasting; immune suppression was associated only with physical QoL. HIV-infected survivors of wasting may represent a population of adults at increased risk for physical function decline.
Authors: Lance E Hultin; Frederick A Menendez; Patricia M Hultin; Beth D Jamieson; Maurice R G O'Gorman; Luann Borowski; Jose L Matud; Thomas N Denny; Joseph B Margolick Journal: Cytometry B Clin Cytom Date: 2007-07 Impact factor: 3.058
Authors: Shabbir M H Alibhai; Henriette Breunis; Narhari Timilshina; Calvin Johnston; George Tomlinson; Ian Tannock; Murray Krahn; Neil E Fleshner; Padraig Warde; Sarah Duff Canning; Lawrence Klotz; Gary Naglie Journal: J Clin Oncol Date: 2010-11-01 Impact factor: 44.544
Authors: Marjolein van Waas; Sebastian J Neggers; Aart-Jan van der Lelij; Rob Pieters; Marry M van den Heuvel-Eibrink Journal: J Pediatr Hematol Oncol Date: 2010-04 Impact factor: 1.289
Authors: Nancy Fugate Woods; Andrea Z LaCroix; Shelly L Gray; Aaron Aragaki; Barbara B Cochrane; Robert L Brunner; Kamal Masaki; Anne Murray; Anne B Newman Journal: J Am Geriatr Soc Date: 2005-08 Impact factor: 5.562
Authors: Philip M Grant; Douglas Kitch; Grace A McComsey; Ann C Collier; Benedetta Bartali; Susan L Koletar; Kristine M Erlandson; Jordan E Lake; Michael T Yin; Kathy Melbourne; Belinda Ha; Todd T Brown Journal: AIDS Date: 2016-11-28 Impact factor: 4.177
Authors: Richard J Hodes; Felipe Sierra; Steven N Austad; Elissa Epel; Gretchen N Neigh; Kristine M Erlandson; Marissa J Schafer; Nathan K LeBrasseur; Christopher Wiley; Judith Campisi; Mary E Sehl; Rosario Scalia; Satoru Eguchi; Balakuntalam S Kasinath; Jeffrey B Halter; Harvey Jay Cohen; Wendy Demark-Wahnefried; Tim A Ahles; Nir Barzilai; Arti Hurria; Peter W Hunt Journal: Ann N Y Acad Sci Date: 2016-12 Impact factor: 5.691
Authors: Kristine M Erlandson; Yuki Bradford; David C Samuels; Todd T Brown; Jing Sun; Kunling Wu; Katherine Tassiopoulos; Marylyn D Ritchie; David W Haas; Todd Hulgan Journal: AIDS Res Hum Retroviruses Date: 2020-01-14 Impact factor: 2.205
Authors: Audrey L Khoury; Miriam C Morey; Tammy C Wong; Donna Lynn McNeil; Barlett Humphries; Katherine Frankey; Carl F Pieper; Charles B Hicks; Kim Huffman; Mehri S McKellar Journal: PLoS One Date: 2017-06-29 Impact factor: 3.240
Authors: Javeed Siddiqui; Shanti K Samuel; Brooke Hayward; Kelly A Wirka; Kathleen L Deering; Qing Harshaw; Amy Phillips; Michael Harbour Journal: AIDS Date: 2022-01-01 Impact factor: 4.177
Authors: Brenda Kitilya; George PrayGod; Robert Peck; John Changalucha; Kidola Jeremiah; Bazil Baltazar Kavishe; Henrik Friis; Suzanne Filteau; Daniel Faurholt-Jepsen; Rikke Krogh-Madsen; Soren Brage; Mette F Olsen Journal: PLoS One Date: 2022-01-21 Impact factor: 3.240